Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer...
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical...
Boston (May 20, 2024)”Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are...
- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated -...
- Stockholders™ equity significantly surpasses the $2.5 million minimum required by Nasdaq - Company is to seek Nasdaq's formal confirmation of compliance with equity requirements under the...
Boston (May 2, 2024)”Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today...
Boston (April 29, 2024) ” Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...
Boston (April 17, 2024)”Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today...
Boston (April 4, 2024) ” Allarity Therapeutics, Inc. (Allarity or the Company) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today...